Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
You may have been too young to remember, but depending on your state’s school immunization requirements, you likely received ...
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
In most cases, adequate hydration and over-the-counter pain relievers can help manage your symptoms during the week or two it ...
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
We get the latest guidance on how to survive the viral season.
Respiratory virus season is arriving, once again, and the La Plata County Public Health Department is urging residents to ...
RSV rates can be expected to increase, and flu, as well as other common viruses. Human metapneumovirus tends to peak in ...
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback